Chad D Hyer

Mr. Chad D Hyer

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2024 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
NZNathan R Zuniga
Nathan R Zuniga
NENoah E Earls
Noah E Earls
ADAriel E A Denos
Ariel E A Denos
JEJared M Elison
Jared M Elison
BJBenjamin S Jones
Benjamin S Jones
JPJohn C Price
John C Price
Apolipoprotein E (ApoE) polymorphisms modify the risk of Alzheimer’s disease with ApoE4 strongly increasing and ApoE2 modestly decreasing risk relative to the control ApoE3. To investigate how ApoE isoforms alter risk, we measured changes in proteome homeostasis in transgenic mice expressing a human ApoE gene (isoform 2, 3, or 4). The regulation of each protein’s homeostasis is observed by measuring turnover rate and abundance for that protein. We identified 4849 proteins and tested for ApoE isoform-dependent changes in the homeostatic regulation of ~2700 ontologies. In the brain, we found that ApoE4 and ApoE2 both lead to modified regulation of mitochondrial membrane proteins relative to the wild-type control ApoE3. In ApoE4 mice, lack of cohesion between mitochondrial membrane and matrix proteins suggests that dysregulation of proteasome and autophagy is reducing protein quality. In ApoE2, proteins of the mitochondrial matrix and the membrane, including oxidative phosphorylation complexes, had a similar increase in degradation which suggests coordinated replacement of the entire organelle. In the liver we did not observe these changes suggesting that the ApoE-effect on proteostasis is amplified in the brain relative to other tissues. Our findings underscore the utility of combining protein abundance and turnover rates to decipher proteome regulatory mechanisms and their potential role in biology. We present a method to quantify and compare in vivo regulation of protein synthesis and degradation for thousands of individual proteins. Using this method, we compare the impact of ApoE isoforms which are known to bias the risk for Alzheimer’s disease. We saw a pattern of changes that links together many published observations in a systematic way to identify biochemical trends increasing the risk of Alzheimer’s disease.

12 May 2024 in Sensors
Verified
Journal Article
Open access
PDF file
TFTyler Free
Tyler Free
TTTalley Talley
Talley Talley
CHChad D Hyer
Chad D Hyer
CMCatherine J. Miller
Catherine J. Miller
JGJoel S. Griffitts
Joel S. Griffitts
BBBradley Charles Bundy
Bradley Charles Bundy
Specialized cancer treatments have the potential to exploit glutamine dependence to increase patient survival rates. Glutamine diagnostics capable of tracking a patient’s response to treatment would enable a personalized treatment dosage to optimize the tradeoff between treatment success and dangerous side effects. Current clinical glutamine testing requires sophisticated and expensive lab-based tests, which are not broadly available on a frequent, individualized basis. To address the need for a low-cost, portable glutamine diagnostic, this work engineers a cell-free glutamine biosensor to overcome assay background and signal-to-noise limitations evident in previously reported studies. The findings from this work culminate in the development of a shelf-stable, paper-based, colorimetric glutamine test with a high signal strength and a high signal-to-background ratio for dramatically improved signal resolution. While the engineered glutamine test is important progress towards improving the management of cancer and other health conditions, this work also expands the assay development field of the promising cell-free biosensing platform, which can facilitate the low-cost detection of a broad variety of target molecules with high clinical value.

27 January 2023 in Journal of Proteome Research
Verified
Journal Article
Open access
CHChad D Hyer
Chad D Hyer
HLHsien-Jung L. Lin
Hsien-Jung L. Lin
CHConnor T. Haderlie
Connor T. Haderlie
MBMonica Berg
Monica Berg
JPJohn C. Price
John C. Price
The structure of a protein defines its function and integrity and correlates with the protein folding stability (PFS). Quantifying PFS allows researchers to assess differential stability of proteins in different disease or ligand binding states, providing insight into protein efficacy and potentially serving as a metric of protein quality. There are a number of mass spectrometry (MS)based methods to assess PFS, such as (T) under bar hermal (P) under bar rotein (P) under bar rofiling (TPP), (S) under bar tability of (P) under bar roteins from (R) under bar ates of (Ox) under bar idation (SPROX), and (I) under bar odination (P) under bar rotein (S) under bar tability (A) under bar ssay (IPSA). Despite the critical value that PFS studies add to the understanding of mechanisms of disease and treatment development, proteomics research is still primarily dominated by concentration-based studies. We found that a major reason for the lack of PFS studies is the lack of a userfriendly data processing tool. Here we present the first user-friendly software, C-Half, with a graphical user interface for calculating PFS. Besides calculating site-specific PFS of a given protein from chemical denature folding stability assays, C-Half is also compatible with thermal denature folding stability assays. C-Half also includes a set of data visualization tools to help identify changes in PFS across protein sequences and in between different treatment conditions. We expect the introduction of C-Half to lower the barrier of entry for researchers to investigate PFS, promoting the usage of PFS in studies. In the long run, we expect this increase in PFS research to accelerate our understanding of the pathogenesis and pathophysiology of disease.

13 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
NZNathan R. Zuniga
Nathan R. Zuniga
NENoah E. Earls
Noah E. Earls
ADAriel E. A. Denos
Ariel E. A. Denos
JEJared M. Elison
Jared M. Elison
BJBenjamin S. Jones
Benjamin S. Jones
JPJohn C. Price
John C. Price
Apolipoprotein E (ApoE) polymorphisms modify the risk of neurodegenerative disease with the ApoE4 isoform increasing and ApoE2 isoform decreasing risk relative to the ‘wild-type control’ ApoE3 isoform. To elucidate how ApoE isoforms alter the proteome, we measured relative protein abundance and turnover in transgenic mice expressing a human ApoE gene (isoform 2, 3, or 4). This data provides insight into how ApoE isoforms affect the in vivo synthesis and degradation of a wide variety of proteins. We identified 4849 proteins and tested for ApoE isoform-dependent changes in the homeostatic regulation of ∼2700 ontologies. In the brain, we found that ApoE4 and ApoE2 both lead to modified regulation of mitochondrial membrane proteins relative to the wild-type control ApoE3. In ApoE4 mice, this regulation is not cohesive suggesting that aerobic respiration is impacted by proteasomal and autophagic dysregulation. ApoE2 mice exhibited a matching change in mitochondrial matrix proteins and the membrane which suggests coordinated maintenance of the entire organelle. In the liver, we did not observe these changes suggesting that the ApoE-effect on proteostasis is amplified in the brain relative to other tissues. Our findings underscore the utility of combining protein abundance and turnover rates to decipher proteome regulatory mechanisms and their potential role in biology. Abstract Figure: For Table of Contents Only